Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Based on TRIUMPH-4 and expected 2026 trial readouts, analysts project NDA submission in Q4 2026 or Q1 2027, FDA approval in mid-to-late 2027, and commercial launch in early 2028
Development and characterization of novel combinations and compositions of nanostructured lipid carrier formulations loaded with trans-resveratrol for pulmonary drug delivery
Glaucoma is a neurodegenerative disease characterized by a progressive decline in RGCs which reside in the optic nerves [71, 94, 95]
One drink occasionally may be tolerated by some patients, but combined effects on stomach emptying and blood sugar increase side effect risk
US$ 21.58
US$ 29.44
US$ 20.63
US$ 21.95
US$ 27.56
US$ 25.46
US$ 22.50
US$ 25.10
US$ 28.53
